Skip to content

Stabilizing Mood and Sleep With Blue Blocking Eyewear in Bipolar Disorder

Stabilizing Mood and Sleep With Blue Blocking Eyewear in Bipolar Disorder

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06271304
Acronym
BLUES
Enrollment
150
Registered
2024-02-21
Start date
2024-04-05
Completion date
2026-06-01
Last updated
2024-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar Disorder

Brief summary

The study investigates whether add-on treatment with eyewear that blocks the short wavelengths of visible light (\<500nm) reduces manic symptoms and improves sleep in patients receiving outpatient treatment as usual for bipolar disorder. When in a hypomanic or manic phase, participants will be randomized to receive add-on treatment with either blue blocking or low filtration eyewear from 18 PM to 8 AM daily for 7 days. After this initial intervention phase, the eyewear is used daily for 3 months in either antimanic dose (14 hours) or maintenance dose (2 hours before bedtime).

Detailed description

The study is a 2-arm single-blind RCT to assess the effects of blue blocking (BB) or clear glasses as an acute 7-day antimanic intervention and as a 3-month mood stabilizing maintenance intervention. BB or clear glasses will be applied in addition to outpatient TAU for BD. Participants will be recruited among patients treated for BD in specialized outpatient clinics within the Mental Health Center Copenhagen. The active intervention is BB-glasses that eliminate 99 % of light with a wavelength below 530 nm, whereas the clear glasses filter out only 15% of short wavelength light (low filtration (LF). Participation includes 3 months use of the designated eyewear along with daily electronic self-monitoring of mood, sleep and activity as well as participation in a 2-day baseline assessment and a total of 3 follow-up visits including clinical assessment interview, questionnaires, and actigraphic (48 hours) and pupillometric assessments at day 9, week 5 and week 15. Participants will be included during hypomanic or manic state and begin treatment with an antimanic dosage of 14 hours (6 PM - 8 AM) for 7 consecutive days. Subsequently, during the 3-month follow-up period, the dosage (hours using the glasses) can be adjusted according to the current state, with use for 14 hours during hypomanic/manic phases and 2 hours before bedtime during euthymic and depressive states. Outcome assessors will be blinded to the treatment assignment and patients will be informed that they are randomized to eyewear with either high or low filtration of light. Patients will be randomized on a 1:1 basis with stratification according to sex and outpatient clinic.

Interventions

DEVICEBlue blocking eyewear

Eyewear is worn daily from 6 PM to 8 AM during manic/hypomanic state Eyewear is worn daily 2 hours before planned bedtime during euthymic, depressive and mixed state

DEVICELow filtration eyewear

Eyewear is worn daily from 6 PM to 8 AM during manic/hypomanic state Eyewear is worn daily 2 hours before planned bedtime during euthymic, depressive and mixed state

Sponsors

Mental Health Services in the Capital Region, Denmark
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Masking description

Participants are instructed not to discuss the appearance of their designated eyewear with their care providers or the investigator or outcome assessor. Participants are not informed of the exact filtration level of their eyewear.

Intervention model description

Outcome assessors will be blinded to the treatment assignment. At the beginning of each assessment, participants will be instructed not to describe or discuss their glasses with the assessor. Because the two types of glasses are of different color (clear (LF) and orange (BB)), we cannot guarantee a full blinding of the participants. Participants will be informed that we are studying the effects of two different types of light filters without more detail so they will not be provided with certain knowledge of which condition is expected to yield the largest effect. We will assess the integrity of the blind by asking participants whether they think they received glasses with high or low filtration lenses at the end of the study. Participants will be discouraged from actively seeking information about sleep glasses during the study

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of bipolar disorder * YMRS-score \>13 * Age 18-60 years * Speaks and writes Danish at a level equal to mother tongue

Exclusion criteria

* Not willing or able to adhere to the protocol * Severe eye disorder or eye trauma * Treatment with betablockers * Sleep disturbances not related to BD (e.g, sleep apnea, restless legs syndrome) • • Substance abuse * Unwilling to use the electronic self-monitoring system, the Monsenso system * Prior/current use of BB glasses * Current/planned pregnancy * Night shift work * Suicidality

Design outcomes

Primary

MeasureTime frameDescription
Manic symptoms7 daysChange in Young Mania Rating Scale Score, range 0-60, higher scores indicating greater manic symptom load

Secondary

MeasureTime frameDescription
Mood instability15 weeksChange in day-to-day variation in electronically self-monitored mood scores
Objective sleep quality7 daysActigraphic measures of sleep latency, sleep time, efficiency and wake periods
Subjective sleep quality7 dayschange in sleep scores from a modified version of the Pittsburgh Sleep Quality Index, range 0-21, higher scores indicating worse sleep quality

Countries

Denmark

Contacts

Primary ContactHelle Madsen, MD
helle.oestergaard.madsen@regionh.dk38 64 70 81

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026